Related Experiment Videos
Gene therapy for bladder cancer using adenoviral vector
1Department of Urology, Kobe University School of Medicine, Kobe, Japan. wada@med.kobe-u.ac.jp
Molecular Urology
|November 3, 2001
Summary
Gene therapy using p53 (a tumor suppressor gene) shows promise for bladder cancer. This approach effectively suppressed tumor growth and improved survival in preclinical models, offering a potential new treatment avenue.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Bladder cancer is a prevalent malignancy.
- Current treatments like bacillus Calmette-Guérin (BCG) are effective in only a subset of patients.
- Over 30% of patients exhibit resistance to adjuvant BCG therapy.
Purpose of the Study:
- To evaluate the feasibility of p53 gene therapy for superficial bladder tumors.
- To investigate the efficacy of targeting p53 mutations common in bladder cancer.
- To assess the potential of intravesical gene delivery for accessible tumors.
Main Methods:
- Transduction of wild-type p53 into human and murine bladder cancer cell lines using Ad5CMV-p53.
- In vitro studies assessing cell growth suppression.
- In vivo studies using subcutaneous bladder tumor models in mice treated with intratumoral Ad5CMV-p53 injections.
Main Results:
- Ad5CMV-p53 significantly suppressed bladder cancer cell growth in vitro.
- Intratumoral Ad5CMV-p53 injection reduced tumor growth rate and volume in vivo.
- Significant improvement in host animal survival was observed in the Ad5CMV-p53 treated group.
Conclusions:
- Ad5CMV-p53 demonstrates effectiveness in suppressing bladder cancer progression.
- Gene therapy with p53 holds potential for improving patient survival in bladder cancer.